Skip to main navigation Skip to search Skip to main content

NECTIN4 amplification (amp) as an actionable alteration in non-small cell lung cancer (NSCLC)

  • J Brägelmann
  • , N Klümper
  • , AA Azizi
  • , EC Colliver
  • , C Kümpers
  • , C Watermann
  • , C Heidel
  • , S Perner
  • , FO Paulsen
  • , M Odenthal
  • , R Büttner
  • , J Wolf
  • , C Kuppe
  • , A Hartmann
  • , M Ritter
  • , V Gruenwald
  • , M Hölzel
  • , C Swanton
  • , M Eckstein

Abstract

Background:NECTIN4 amp has emerged as a promising predictive biomarker for
Nectin-4 targeting therapies. In the Phase I/II Duravelo-1 trial (NCT04561362),
zelenectide pevedotin, a Nectin-4—targeting Bicycle®Drug Conjugate, showed a 40%
response rate in NECTIN4-amp vs. 0% in without NECTIN4-amp NSCLC (Verlingue,
ELCC 2025), leading to its FDA Fast Track Designation in previously treated NECTIN4-
amp NSCLC (investigated in Duravelo-4, NCT06933329). Here, we elucidate Nectin-4’s
biological and clinical significance using tissue microarrays (TMAs) and genomic
datasets.
Methods: TMAs from three academic centers were assessed for NECTIN4 copy-
number (FISH) and membranous protein expression (IHC) as described previously
(Klümper, JCO, 2024). Own whole-exome sequencing (WES) and RNA-seq of 106
NSCLC samples and TCGA cohorts were analyzed for NECTIN4 status, clinical out
comes, co-occurring mutations, transcriptional profiles and immune infiltration.
Annals of Oncology abstracts
S258 Volume 36■ Issue S2■2025
Results: In TMAs, 20% of NSCLC samples showed NECTIN4 amp and 7.3% polysomy.
NECTIN4 FISH correlated significantly with membranous protein expression (p<10-10,
H-scores 130 and 0 with interquartile ranges 133 and 20 for NECTIN4-amp and non-
amp, respectively), with RNA expression (p=0.001) and with WES-based copy
number (p<0.001). In our own sequencing cohort, NECTIN4 amp was associated with
KRAS mutations (p=0.041) and history of smoking (p=0.043), but not with overall
survival, other therapeutically relevant genomic alteration and clinical parameters. In
NECTIN4 amp tumors, expression of gene sets related to epithelial mesenchymal
transition (EMT), inflammation and active immune response were significantly
downregulated. Similarly, NECTIN4 expression correlated with ERBB2/ERBB3
expression, but inversely with expression of AXL, PDCD1 (PD1) & CTLA4 as well as
estimated levels of infiltrating T cells and overall immune cell content.
Conclusions:Our multi-cohort analysis establishes NECTIN4 amp as a relevant NSCLC
subgroup with low EMT and immune activity. Combined with the enhanced efficacy of
zelenectide pevedotin in NECTIN4-amp NSCLC in Duravelo-1, these findings support
NECTIN4 amp as a promising predictive biomarker for precision oncology in NSCLC.
Original languageGerman
Article number161P
JournalAnnals of Oncology
Volume36
Pages (from-to)258
Number of pages259
ISSN0923-7534
DOIs
Publication statusPublished - 2025

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

  1. SDG 3 - Good Health and Well-being
    SDG 3 Good Health and Well-being

Cite this